Literature DB >> 31054454

Schizotypal personality disorder in individuals with the Attenuated Psychosis Syndrome: Frequent co-occurrence without an increased risk for conversion to threshold psychosis.

Anthony W Zoghbi1, Joel A Bernanke2, Julia Gleichman2, Michael D Masucci2, Cheryl M Corcoran3, Allegra Califano2, Justin Segovia2, Tiziano Colibazzi2, Michael B First2, Gary Brucato2, Ragy R Girgis2.   

Abstract

The Attenuated Psychosis Syndrome (APS), proposed as a condition warranting further study in the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), is a controversial diagnostic construct originally developed to identify individuals at clinical high-risk for psychosis. The relationship of APS and Schizotypal Personality Disorder (SPD) remains unclear with respect to their potential co-occurrence and the effect of SPD on risk for conversion to threshold psychosis. We examined the prevalence and effect on conversion of SPD in a cohort of 218 individuals whose symptoms met APS criteria. Results indicated that SPD was highly prevalent (68%), and that SPD did not influence risk for conversion. Rather, total positive symptom burden measured by the Structured Interview for Psychosis-Risk Syndromes (SIPS; OR 1.12, p = 0.02) emerged as the strongest predictor of conversion. These data suggest that when encountering a patient whose presentation meets SPD criteria, the clinician should assess whether APS criteria are also met and, for 1-2 years, carefully monitor positive symptoms for possible conversion to threshold psychosis.
Copyright © 2019. Published by Elsevier Ltd.

Entities:  

Keywords:  Attenuated psychosis syndrome; Clinical high-risk for psychosis; Prodromal psychosis; Schizotypal personality disorder; Schizotypy

Mesh:

Year:  2019        PMID: 31054454      PMCID: PMC6546532          DOI: 10.1016/j.jpsychires.2019.04.018

Source DB:  PubMed          Journal:  J Psychiatr Res        ISSN: 0022-3956            Impact factor:   4.791


  20 in total

Review 1.  Attenuated psychosis syndrome in DSM-5.

Authors:  Ming T Tsuang; Jim Van Os; Rajiv Tandon; Deanna M Barch; Juan Bustillo; Wolfgang Gaebel; Raquel E Gur; Stephan Heckers; Dolores Malaspina; Michael J Owen; Susan Schultz; William Carpenter
Journal:  Schizophr Res       Date:  2013-06-14       Impact factor: 4.939

2.  Baseline demographics, clinical features and predictors of conversion among 200 individuals in a longitudinal prospective psychosis-risk cohort.

Authors:  G Brucato; M D Masucci; L Y Arndt; S Ben-David; T Colibazzi; C M Corcoran; A H Crumbley; F M Crump; K E Gill; D Kimhy; A Lister; S A Schobel; L H Yang; J A Lieberman; R R Girgis
Journal:  Psychol Med       Date:  2017-03-02       Impact factor: 7.723

3.  Transition rates from schizotypal disorder to psychotic disorder for first-contact patients included in the OPUS trial. A randomized clinical trial of integrated treatment and standard treatment.

Authors:  Merete Nordentoft; Anne Thorup; Lone Petersen; Johan Ohlenschlaeger; Marianne Melau; Torben Østergaard Christensen; Gertrud Krarup; Per Jørgensen; Pia Jeppesen
Journal:  Schizophr Res       Date:  2006-02-28       Impact factor: 4.939

Review 4.  Size of burden of schizophrenia and psychotic disorders.

Authors:  Wulf Rössler; Hans Joachim Salize; Jim van Os; Anita Riecher-Rössler
Journal:  Eur Neuropsychopharmacol       Date:  2005-08       Impact factor: 4.600

5.  Prediction of psychosis in adolescents and young adults at high risk: results from the prospective European prediction of psychosis study.

Authors:  Stephan Ruhrmann; Frauke Schultze-Lutter; Raimo K R Salokangas; Markus Heinimaa; Don Linszen; Peter Dingemans; Max Birchwood; Paul Patterson; Georg Juckel; Andreas Heinz; Anthony Morrison; Shôn Lewis; Heinrich Graf von Reventlow; Joachim Klosterkötter
Journal:  Arch Gen Psychiatry       Date:  2010-03

6.  Self-experience in the early phases of schizophrenia: 5-year follow-up of the Copenhagen Prodromal Study.

Authors:  Josef Parnas; Andrea Raballo; Peter Handest; Lennart Jansson; Anne Vollmer-Larsen; Ditte Saebye
Journal:  World Psychiatry       Date:  2011-10       Impact factor: 49.548

7.  Diagnosing schizophrenia in the initial prodromal phase.

Authors:  J Klosterkötter; M Hellmich; E M Steinmeyer; F Schultze-Lutter
Journal:  Arch Gen Psychiatry       Date:  2001-02

8.  North American Prodrome Longitudinal Study (NAPLS 2): The Prodromal Symptoms.

Authors:  Jean Addington; Lu Liu; Lisa Buchy; Kristin S Cadenhead; Tyrone D Cannon; Barbara A Cornblatt; Diana O Perkins; Larry J Seidman; Ming T Tsuang; Elaine F Walker; Scott W Woods; Carrie E Bearden; Daniel H Mathalon; Thomas H McGlashan
Journal:  J Nerv Ment Dis       Date:  2015-05       Impact factor: 2.254

9.  Personalized Prediction of Psychosis: External Validation of the NAPLS-2 Psychosis Risk Calculator With the EDIPPP Project.

Authors:  Ricardo E Carrión; Barbara A Cornblatt; Cynthia Z Burton; Ivy F Tso; Andrea M Auther; Steven Adelsheim; Roderick Calkins; Cameron S Carter; Tara Niendam; Tamara G Sale; Stephan F Taylor; William R McFarlane
Journal:  Am J Psychiatry       Date:  2016-07-01       Impact factor: 18.112

10.  Preliminary findings for two new measures of social and role functioning in the prodromal phase of schizophrenia.

Authors:  Barbara A Cornblatt; Andrea M Auther; Tara Niendam; Christopher W Smith; Jamie Zinberg; Carrie E Bearden; Tyrone D Cannon
Journal:  Schizophr Bull       Date:  2007-04-17       Impact factor: 9.306

View more
  2 in total

1.  Attenuated Resting-State Functional Anticorrelation between Attention and Executive Control Networks in Schizotypal Personality Disorder.

Authors:  Ji-Won Hur; Taekwan Kim; Kang Ik K Cho; Jun-Soo Kwon
Journal:  J Clin Med       Date:  2021-01-15       Impact factor: 4.241

2.  DSM-5 Attenuated Psychosis Syndrome in Adolescents Hospitalized With Non-psychotic Psychiatric Disorders.

Authors:  Gonzalo Salazar de Pablo; Daniel Guinart; Barbara A Cornblatt; Andrea M Auther; Ricardo E Carrión; Maren Carbon; Sara Jiménez-Fernández; Ditte L Vernal; Susanne Walitza; Miriam Gerstenberg; Riccardo Saba; Nella Lo Cascio; Martina Brandizzi; Celso Arango; Carmen Moreno; Anna Van Meter; Paolo Fusar-Poli; Christoph U Correll
Journal:  Front Psychiatry       Date:  2020-10-21       Impact factor: 4.157

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.